The findings of three retrospective studies provide valuable insights into the burden of bronchiectasis across different ...

In patients with moderate-to-severe allergic asthma, tezepelumab yields the greatest reduction in exacerbations among ...

Modulator therapy does not appear to affect the magnitude of lung function impairment or recovery pattern during pulmonary ...

Patients hospitalized for acute COPD exacerbation had reduced odds for in-hospital mortality if they had a prior history of bariatric surgery, according to data presented at the CHEST Annual Meeting.“ ...

Regardless of blood eosinophil count threshold, adults with COPD and an eosinophilic phenotype experienced significantly fewer moderate/severe exacerbations in a year with mepolizumab vs. placebo, ...

In severe asthma, more exacerbations occur November through January, with respiratory infection as the most commonly identified trigger.

Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...

About 30 to 40% of children with asthma experience sleep difficulties due to symptoms like coughing and wheezing. Poor sleep ...